Pralatrexate
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PRALATREXATE |
|---|---|
| Type | Drug |
| Aliases | FolotynПралатрексат |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PTCL-NOS |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Antifolate (selective for RFC-1 transporter — accumulates in malignant T-cells) |
|---|---|
| Mechanism | Folate analog with high affinity for reduced folate carrier-1 (RFC-1) transporter, selectively accumulating in malignant T-cells and inhibiting dihydrofolate reductase (DHFR). Internal polyglutamation traps the drug intracellularly. Mechanism distinct from methotrexate — designed for selective uptake in T-cell malignancies. |
| Typical dosing | 30 mg/m² IV push over 3-5 min, weekly × 6 of every 7-week cycle, until progression or unacceptable toxicity |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Mucositis — common and dose-limiting; can be severe
- Cytopenias — anemia, neutropenia, thrombocytopenia
Notes
PROPEL trial (O'Connor 2011): r/r PTCL n=111 (incl PTCL NOS, AITL, ALCL ALK-, transformed MF) — ORR 29%, CR 11%, mDOR 10.1 mo. FDA- approved for r/r PTCL after ≥1 prior line. Mucositis is dominant dose-limiting toxicity — MANDATORY folate 1 mg PO daily + vitamin B12 1 mg IM every 8-10 weeks throughout therapy + oral cryotherapy / cold-water gargle during infusion to mitigate. Major UA access barrier: not registered + not EMA-approved.
Used By
Regimens
REG-PRALATREXATE-PTCL- Pralatrexate 30 mg/m² IV weekly × 6 of 7-week cycle (PROPEL schedule) — r/r PTCL